Elevated expression of IL-3Rα is associated with enhanced blast proliferation and a poor prognostic phenotype in patients with AML, indicating that CD123 is a promising therapeutic target for leukemia therapy [24–26]. The gene discussed is IL3RA; the disease is acute myeloid leukemia.